久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Innovation

Dedication, team work boost China's COVID-19 research

Xinhua | Updated: 2022-03-29 14:33
Share
Share - WeChat
Zhang Linqi, leading scientist in developing China's first approved COVID-19 antibody drug, demonstrates a model of protein on the surface of the novel coronavirus. [Photo provided to chinadaily.com.cn]

BEIJING -- Many clinicians have referred to a COVID-19 drug developed by Zhang Linqi as a "miracle medicine" after seeing their patients' lasting fever symptoms diminish quickly following an injection of the drug.

A virologist at China's Tsinghua University, Zhang led his team to create a cocktail therapy of monoclonal antibodies BRII-196 and BRII-198, which cut hospitalizations and deaths by 80 percent in human trials and appears to work well against all existing variants.

It took just 18 months for the Chinese drug to be developed and receive regulatory approval.

"In less than two years, we finished a job that would otherwise take at least 10 years," Zhang said.

His latest research uses a deep learning approach to help his team obtain antibodies that can neutralize the coronavirus and its variants at a faster pace.

Anti-COVID-19 research results from Chinese institutes, universities and enterprises have been published in international academic journals every two or three days since January. Chinese scientists are contributing their wisdom, experience and painstaking efforts to enhance the human capacity to cope with the deadly virus.

While the Academy of Military Medical Sciences presented an mRNA COVID-19 antibody that provided lasting immunity in mice, Fudan University created an adenovirus vaccine candidate designed to give dual protection against both COVID-19 and influenza viruses.

Researchers at the Chinese Academy of Sciences (CAS), China's top academic institute, are working on an inhalable antibody with low cost and large-scale production advantages, while pharmaceutical companies in Shanghai and Suzhou have commenced global trials of a co-developed oral drug for moderate and severe COVID-19 cases.

Speaking to press at the fifth session of the 13th National People's Congress earlier in March, Minister of Science and Technology Wang Zhigang said that China has had fruitful beginning to its development of COVID-19 vaccines and drugs, with several candidates being granted market approval or undergoing clinical trials.

"The more tools to tackle COVID-19 that science and technology can provide, the better our anti-pandemic measures can become," the minister said.

None of this progress has come easily. China's impressive pace of medical research is the result of the long-term hard work of Chinese scientists.

Wang Qihui is a CAS virologist. Since January 2020, when Wang first volunteered to work on COVID-19, she has been racing against the clock to find ways to defeat the virus.

Tasked with finding effective antibodies in a short time, Wang led her team to conduct experiments day and night. She once stayed in her laboratory for two weeks, sometimes forgetting food and sleep.

Five months after the initial outbreak of the novel coronavirus, her team announced that JS016, a COVID-19-neutralizing antibody that they had developed, could be administered to healthy people in clinical trials. In November last year, the antibody was granted emergency-use authorization in 15 countries, including the United States and several European countries.

Lots of sacrifices were made in this process. Right before the results of the COVID-19 antibody study came out, Wang Qihui experienced neurological deafness because of high stress, which led to temporary hearing loss in her left ear.

She was hospitalized for five days after a doctor warned her that, in the absence of timely treatment, she could develop permanently impaired hearing.

The scientist has since recovered and is determined to make greater contribution to the fight against the pandemic. She has resumed her COVID-19 research, working to develop a nasal spray antibody drug and an mRNA vaccine.

Wang Qihui attributes her achievements largely to her previous experience in the field of viral infectious diseases, such as Middle East Respiratory Syndrome (MERS) and the Zika virus.

Zhang Linqi and his team, like Wang, have used their determination and wealth of experience in responding to new pathogens to deal with the pandemic.

Zhang has devoted 30 years to the study of HIV-1 pathogenesis and vaccine development, and to emerging and re-emerging human viral pathogens such as MERS, Ebola and the Zika virus.

"The development of a treatment drug and a vaccine sounded lighting fast, even to me, but it benefited from years of research on antibody drugs and HIV vaccine development," Zhang said when asked how the COVID-19 antibody drug he developed was created so quickly.

Inspired by the "AIDS cocktail," a combination treatment of three or four different medicines for people with HIV/AIDS, Zhang and his team selected 206 monoclonal antibodies and whittled the number down to two, creating their COVID-19 cocktail therapy.

It has demonstrated an improved performance in resisting virus mutations and maintained longer activity in the human body compared to similar therapies consisting of only one antibody.

Xiamen University, which has also accumulated significant experience in vaccine development, is a major research force in the fight against COVID-19. It was also one of the first institutions to receive global virus research donations.

Emerging technologies are involved in COVID-19 research. Tech giant Baidu has licensed its mRNA sequencing algorithm to French vaccine maker Sanofi for use in the design of COVID-19 vaccines and therapeutic products. According to the Chinese company, the algorithm can accelerate the research.

Zhang also stressed that interdisciplinary collaboration is very important in his work. He collaborated with Tsinghua biologists to decipher the structure of the virus, and with Shenzhen clinicians to isolate monoclonal antibodies in convalescent patients. These partnerships accelerated the development of China's first COVID-19 antibody drug.

"Scientific research is to explore the unknown in blind zones. We scientists not only need strong hearts and big brains, but also partners to support us. Even if we fail, we are not alone, as there are many people supporting us," Zhang said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

    日本久久久精品视频| 国产成人在线免费看| 成年人午夜免费视频| 亚洲第一中文av| 9色视频在线观看| 国产精品乱码久久久久| 日韩精品视频一区二区在线观看| 亚洲色图欧美自拍| 欧美一区二区激情| 亚洲福利精品视频| 老汉色影院首页| 粗暴91大变态调教| 在线播放黄色av| av在线观看地址| 中文字幕 日韩 欧美| 蜜臀av色欲a片无码精品一区| 免费看a级黄色片| 日本xxx免费| 密臀av一区二区三区| 成年人深夜视频| 老司机午夜性大片| 日韩a级在线观看| aaa一级黄色片| 男人揉女人奶房视频60分| 久久精品久久99| 国产在线青青草| 日韩成人手机在线| 艹b视频在线观看| 国产玉足脚交久久欧美| www.午夜av| 日本女优爱爱视频| 男的插女的下面视频| 午夜精品免费看| 欧美视频第一区| 日韩视频一二三| 天堂av手机在线| 亚洲不卡视频在线| 黄色av网址在线播放| 永久免费网站视频在线观看| 黄色手机在线视频| 免费观看国产精品视频| 黄色网址在线免费看| 黑森林精品导航| 国产精品入口芒果| 成人小视频在线观看免费| 最新黄色av网站| 400部精品国偷自产在线观看| 牛夜精品久久久久久久| 成人毛片视频网站| a级黄色小视频| 欧美两根一起进3p做受视频| 欧美极品少妇无套实战| 伊人国产精品视频| 婷婷免费在线观看| 黄色高清无遮挡| 国产精品免费观看久久| 少妇高潮喷水在线观看| 国产1区2区3区中文字幕| 国产黑丝在线视频| 欧美激情第一区| 天天摸天天舔天天操| 四季av一区二区| 日韩 欧美 高清| 欧美日韩一区二区在线免费观看 | 亚欧精品在线视频| 国产一级不卡毛片| 99色精品视频| 日本男女交配视频| 自拍偷拍视频在线| 黄色一级视频播放| 国产日产欧美一区二区| 麻豆md0077饥渴少妇| 永久av免费在线观看| 特级黄色片视频| 精品91一区二区三区| 国产卡一卡二在线| av片在线免费| 国产成人一区二区三区别| 久久天天东北熟女毛茸茸| 99久re热视频精品98| 国产在线无码精品| 欧美这里只有精品| 国产精品裸体瑜伽视频| 免费在线观看亚洲视频| 99爱视频在线| 少妇性l交大片| 色91精品久久久久久久久| 色乱码一区二区三区在线| 九九久久久久久| 阿v天堂2017| 做a视频在线观看| 欧美视频在线观看视频| 99福利在线观看| jizzzz日本| 国产免费内射又粗又爽密桃视频| 岛国大片在线播放| 毛片av免费在线观看| 中文字幕线观看| 屁屁影院ccyy国产第一页| 国产精品国产亚洲精品看不卡 | 日韩爱爱小视频| 一级网站在线观看| 91成人综合网| 青青在线视频免费| 精品久久免费观看| 欧美中日韩在线| 又色又爽又高潮免费视频国产| 激情黄色小视频| 97在线免费视频观看| 国内外成人激情视频| 久久久久久香蕉| 色综合色综合色综合色综合| 日韩不卡视频一区二区| 免费看国产曰批40分钟| 青青青在线播放| 91福利免费观看| 成年女人18级毛片毛片免费| 91香蕉视频污版| 成人在线免费高清视频| 一本久道中文无码字幕av| 国产精品嫩草影视| 黄色影院一级片| 北条麻妃亚洲一区| 久久久免费视频网站| 1314成人网| 国产午夜福利视频在线观看| 黄色一级视频播放| 男生操女生视频在线观看| 十八禁视频网站在线观看| 日韩一级免费看| 91国视频在线| 国内av免费观看| 日韩一级在线免费观看| 日本成人在线不卡| 国内国产精品天干天干| 久久视频这里有精品| 国产又爽又黄ai换脸| 91视频免费版污| 日韩精品久久一区二区| 久久这里只精品| 久久久999免费视频| 国产成人美女视频| 777久久久精品一区二区三区| 一级一片免费播放| 中文字幕永久视频| 亚洲精品蜜桃久久久久久| 三日本三级少妇三级99| 日本少妇高潮喷水视频| 美女在线免费视频| 爱豆国产剧免费观看大全剧苏畅 | 乱熟女高潮一区二区在线| 91极品视频在线观看| 大j8黑人w巨大888a片| 成人手机在线播放| 老司机午夜性大片| 好男人www社区| 99精品人妻少妇一区二区| av动漫在线免费观看| 91精品视频国产| 手机在线免费观看毛片| 国产亚洲精品网站| 五十路熟女丰满大屁股| 浴室偷拍美女洗澡456在线| 欧美成人三级在线播放| 粗暴91大变态调教| 欧美国产视频一区| 国产香蕉一区二区三区| 在线一区二区不卡| 欧美成人福利在线观看| 超碰在线97免费| 日本免费观看网站| 欧美伦理视频在线观看| 免费日韩视频在线观看| 啊啊啊一区二区| 久色视频在线播放| 成人午夜免费在线| 婷婷无套内射影院| 欧美 亚洲 视频| 天天做天天躁天天躁| 国内外成人免费在线视频| 少妇高潮喷水久久久久久久久久| 成人在线国产视频| 久久久天堂国产精品| 青青草原国产在线视频| 亚洲性生活网站| 亚洲少妇第一页| 蜜臀久久99精品久久久酒店新书| 啊啊啊一区二区| av一区二区三区免费观看| 中文字幕 欧美日韩| 中文字幕22页| 国产福利精品一区二区三区| 无遮挡又爽又刺激的视频 | 亚洲无在线观看| 亚洲国产午夜精品| 波多野结衣激情| 欧美日韩激情四射| 精品国产一区三区| 北条麻妃av高潮尖叫在线观看| 99视频在线视频|